Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Current Cancer Therapy Reviews
Title:Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Volume: 12 Issue: 1
Author(s): Bahar Bahrani, Hannah Liu, Elizabeth M Marchionne and Amor Khachemoune
Affiliation:
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Abstract: Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Export Options
About this article
Cite this article as:
Bahrani Bahar, Liu Hannah, Marchionne M Elizabeth and Khachemoune Amor, Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160714151154
DOI https://dx.doi.org/10.2174/1573394712666160714151154 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potentials of Recently Identified PLD Inhibitors
Current Chemical Biology Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring
Current Proteomics Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry Regulation of Intestinal Barrier Function by Dietary Polyphenols
Current Nutrition & Food Science Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System
Current Medicinal Chemistry Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease
Current Bioactive Compounds Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets